Feedback / Questions
zetomipzomib (KZR-616) - Kezar
https://www.businesswire.com/news/home/20250325918238/en/Kezar-Life-Sciences-Announces-Positive-Topline-Results-from-the-PORTOLA-Phase-2a-Trial-Evaluating-Zetomipzomib-for-the-Treatment-of-Patients-with-Autoimmune-Hepatitis-AIH-and-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results
Mar 25, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next